Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

European Investment Bank (EIB)

Investor type Government Office

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 234
Average round size
info
The average size of a deal this fund participated in
$111M
Portfolio companies 211
Rounds per year 3.60
Lead investments 85
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.09
Exits 56
Key employees 10
Stages of investment
Debt
Grant

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Software
  • Information Technology
Summary

European Investment Bank (EIB) is the famous Corporate Investor, which was founded in 1958. The venture was found in Europe in Luxembourg. The main office of represented Corporate Investor is situated in the Luxembourg.

The typical startup value when the investment from European Investment Bank (EIB) is more than 1 billion dollars. The usual things for fund are deals in the range of 50 - 100 millions dollars. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in 7-12 investment rounds annually. This European Investment Bank (EIB) works on 8 percentage points less the average amount of lead investments comparing to the other organizations. Speaking about the real fund results, this Corporate Investor is 52 percentage points more often commits exit comparing to other organizations. The increased amount of exits for fund were in 2018.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - Finland. Besides, a startup requires to be at the age of 11-15 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Internet, Financial Services. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Among the various public portfolio startups of the fund, we may underline IZettle, Better Place, Gigaclear

The usual cause for the fund is to invest in rounds with 1-2 partakers. Despite the European Investment Bank (EIB), startups are often financed by Bayern Kapital GmbH, Tesi, 360 Capital Partners. The meaningful sponsors for the fund in investment in the same round are AXA Group, Unternehmertum Venture Capital Partners, Positive Planet. In the next rounds fund is usually obtained by AXA Group, Tesi, Funds managed by Maj Invest.

Besides them, we counted 6 critical employees of this fund in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of European Investment Bank (EIB):
Typical Co-investors
European Investment Bank (EIB) is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after European Investment Bank (EIB):

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

O3b Networks

Enterprise Software
Internet
Mobile
Telecommunications
Wireless
$354M11 Jan 2023 The Hague, South Holland, Netherlands

ExeVir Bio

Biotechnology
Health Care
Life Science
Therapeutics
$29M09 Jan 2023 Ghent, East Flanders, Belgium

Cellectis

Biopharma
Biotechnology
Health Care
Medical
$47M28 Dec 2022 Paris, Ile-de-France, France

Affibody

Biotechnology
Health Care
Health Diagnostics
$23M23 Dec 2022 Stockholm, Stockholm County, Sweden

AB Science

Biotechnology
Life Science
Pharmaceutical
$7M22 Dec 2022 Paris, Ile-de-France, France

Vesteda

Property Management
Real Estate
Real Estate Investment
$177M21 Dec 2022 Amsterdam, Noord-Holland, The Netherlands

RE:OCEAN

Farming
$63M20 Dec 2022 -

Metso Outotec

Machinery Manufacturing
Mineral
Mining
Recycling
Sustainability
$59M15 Dec 2022 Helsinki, Southern Finland, Finland

DeepUll

Biotechnology
Diagnostic Equipment
Life Science
Therapeutic Devices
$23M13 Dec 2022 Barcelona, Catalonia, Spain
News
OSE Immunotherapeutics Enters a Loan Agreement of up to €25 Million with the European Investment Bank

– OSE Immunotherapeutics entered a loan agreement of up to €25 million with the European Investment Bank.
– The loan facility is divided into three tranches including two tranches of €10 million each and a third tranche of €5 million.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent European Investment Bank (EIB)?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: